Hey guys I just wanted to create a thread discussing some of the differences between Ryoncil and Jakafi trial results prior to approval/rejection from the fda. From what I understand Novartis did a single arm trial with only a small number of patients prior to approval due to it demonstrating approx 69% overall response rate vs around 30% in the standard care group however there were significant adverse events such as thrombocytopenia, anaemia and cytomegalovirus etc. I get that Jakafi was already approved for other conditions and has a defined MOA but how can you turn down Ryoncil and not Jakafi with their relative safety profiles. Why can’t mesoblast perform a retrospective study on their patients in Japan and use that to support efficacy etc
- Forums
- ASX - By Stock
- MSB
- Ruxolitinib vs Ryoncil
Ruxolitinib vs Ryoncil
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B |
Open | High | Low | Value | Volume |
$1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 99680 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.16 | 31000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 99680 | 1.150 |
4 | 178484 | 1.145 |
3 | 40155 | 1.140 |
1 | 23155 | 1.135 |
3 | 88145 | 1.130 |
Price($) | Vol. | No. |
---|---|---|
1.155 | 31000 | 2 |
1.160 | 77919 | 3 |
1.165 | 2000 | 1 |
1.170 | 45455 | 3 |
1.175 | 49449 | 5 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |